United States soft tissue sarcoma market is poised to witness significant growth until 2025 owing to the rise in pool of patients suffering from different types of cancers including soft tissue sarcoma. The government’s focus on providing best healthcare facilities and increasing funding for the development of new drugs are some key factors supporting the growth of soft tissue sarcoma market. Moreover, rising awareness among people about chronic diseases such as soft tissue sarcoma is also acting as a major factor behind the market growth. Moreover, the
Soft tissue sarcoma is a rare type of cancer
United States soft tissue sarcoma market can be segmented based on
Major companies operating in United States soft tissue sarcoma market include GlaxoSmithKline LLC, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb Co, Hoffmann-La Roche Inc, Johnson & Johnson Services, Inc., Teva Pharmaceuticals USA Inc, Celgene Corporation, BioHorizons, Zimmer Biomet Holdings Inc and MiMedx Group Inc, among others. With the use of latest technologies, manufacturers are focusing on launching new drugs which can be more effective for treatment of soft tissue sarcoma.
Years considered for this report
Historical Years2015-2018
Base Year2019
Estimated Year2020
Forecast Period2021–2025
Objective of the Study
- To analyze and forecast the market size of United States soft tissue sarcoma market.
- To forecast United States soft tissue sarcoma market based on treatment, disease type, end user, company and regional distribution.
- To identify drivers and challenges for United States soft tissue sarcoma market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in United States soft tissue sarcoma market.
- To identify and analyze the profile of leading players operating in the United States soft tissue sarcoma market.
Click here to download the s
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of soft tissue sarcoma treatment companies across United States. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.
TechSci Research calculated United States soft tissue sarcoma market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.
Key Target Audience
- Soft tissue sarcoma drug manufacturers, companies/partners, hospital/oncology centers and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, industry associations, forums and alliances related to soft tissue sarcoma
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as soft tissue sarcoma drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
